In a groundbreaking investigation carried out by a collaborative team from Genomics England, the National Health Service (NHS) England, Queen Mary University of London, the University of Westminster, and Guy’s and St Thomas’ NHS Foundation Trust, researchers have unveiled the potential of significantly enhancing cancer treatment by merging whole-genome sequencing with clinical data. The study unveiled in Nature Medicine, explores the prospect of incorporating genomic sequencing into regular medical practices for specific cancers in the UK.
Insights into the Study
The research delved into 33 types of solid tumors from a participant pool of 13,800 individuals as part of the UK’s ambitious 100,000 Genomes Project. Employing the potent Illumina HiSeq platform for genetic analysis, the scientists expanded their examination beyond genetic data. They scrutinized patients’ clinical records, encompassing hospital visits, prescribed treatments, and treatment responses. This comprehensive methodology enabled a more profound understanding of how cancer manifests at the genetic level and reacts to diverse treatments.
Key Revelations
The outcomes were enlightening. The researchers discerned that employing whole-genome sequencing yielded more nuanced and practical information compared to conventional cancer panels. Specific genetic alterations in brain, colon, and lung cancers were identified, offering guidance for future treatment strategies. In the case of sarcomas, a rare cancer type, approximately 10% of tumors exhibited distinctive genetic variations with potential applications for similar purposes. Moreover, the scientists pinpointed genetic changes capable of predicting treatment response and forecasting overall patient outcomes.
Advocacy for Integration
These revelations robustly advocate for an expanded use of whole-genome sequencing within the NHS Genomic Medicine Service, inaugurated in 2018. Nirupa Murugaesu, a principal clinician specializing in cancer genomics and clinical studies at Genomics England, credited the 100,000 Genomes Project as the precursor to this study. She highlighted that whole-genome sequencing furnishes a “comprehensive inventory” of genomic alterations, supplying a plethora of information crucial for making informed treatment decisions. This has propelled the endorsement of whole-genome sequencing for specific cancers, including glioma, sarcoma, and high-grade serous ovarian cancer.
Present and Future Application
Whole-genome sequencing is recommended for select cancers such as glioma, sarcoma, high-grade serous ovarian cancer, pediatric cancers, and acute leukemias. Nevertheless, for other cancer types, the prevailing norm involves the utilization of targeted cancer panels. Researchers envisage a paradigm shift over time, particularly with the diminishing costs associated with whole-genome sequencing. Matt Brown, Chief Scientific Officer at Genomics England, expressed anticipation for “further changes toward whole-genome sequencing and away from panels over time.”
Upcoming Research Endeavors
Genomics England is actively immersed in ongoing research initiatives. These include the exploration of long-read sequencing platforms for assessing diverse cancers like leukemias, gliomas, and sarcomas. Additionally, they are constructing an extensive dataset that encompasses not only genetic information but also histopathology and imaging data from participants in the 100,000 Genomes Project. This dataset is being fine-tuned for artificial intelligence (AI) applications, signaling the potential integration of advanced computing systems in comprehending and treating cancer.
This study signifies a momentous leap forward in cancer research and treatment. By amalgamating advanced genetic sequencing with clinical data, scientists are unraveling invaluable insights that can steer more personalized and efficacious treatments for cancer patients. As technological advancements persist and costs dwindle, the trajectory of cancer care in the UK may indeed witness a shift toward whole-genome sequencing as a standard procedure.
Read more on our website!
